Interferon-free anti-viral therapy for chronic hepatitis C

Abstract

The analysis of the interferon-free regimen of antiviral therapy in combination with the latest nucleotide polymerase inhibitors (ledipasvir/sofosbuvir for 12 weeks) provided high rates of sustained virological response among patients with chronic hepatitis C (CHC) infected with the "1B" genotype, both in previously untreated patients (100 %) and treated (94.1 %). The combination of drugs with direct antiviral effect, significantly reduces the risk of resistance, and liver fibrosis. The interferon-free regimen of antiviral therapy practically does not depend on the factors that determined the effectiveness of treatment with pegeled interferon and ribavirin, which made it possible to completely exclude interferons from the treatment regimen for hepatitis C and achieve a significant increase in the effectiveness of therapy. The use of direct antiviral drugs in CHC has reduced the duration of the course of therapy, increased the convenience of use, and expanded the indications for treatment of patients who previously had no chance. In addition, the achievement of a stable virological response contributes to the implementation of anti-epidemic measures, affecting the first link of the epidemic process — the source of infection.